Worldquant Millennium Advisors LLC Has $54.65 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Worldquant Millennium Advisors LLC grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 20.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 132,193 shares of the company's stock after purchasing an additional 21,997 shares during the quarter. Worldquant Millennium Advisors LLC owned about 0.16% of IDEXX Laboratories worth $54,654,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Hurley Capital LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $29,000. Rialto Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $30,000. Colonial Trust Co SC lifted its stake in shares of IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after purchasing an additional 39 shares during the period. Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $38,000. Finally, Itau Unibanco Holding S.A. raised its stake in IDEXX Laboratories by 540.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after buying an additional 81 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on IDXX. Stifel Nicolaus raised their price objective on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday. StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Barclays raised their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Piper Sandler raised their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Finally, Bank of America raised their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and an average target price of $536.00.

IDEXX Laboratories Price Performance

IDXX stock opened at $521.68 on Tuesday. The stock has a 50-day moving average price of $433.47 and a two-hundred day moving average price of $432.18. The stock has a market cap of $41.95 billion, a PE ratio of 48.89, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $545.43.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company's revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.71 EPS. Equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.